查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2032553

神經調控市場報告：按技術、生物材料、應用和地區分類（2026-2034 年）

Neuromodulation Market Report by Technology, Biomaterial, Application, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

2025年全球神經調控市場規模達89億美元。展望未來，IMARC Group預測，2026年至2034年該市場將以8.48%的複合年成長率成長，到2034年達到190億美元。該市場正經歷強勁成長，其促進因素包括慢性病和神經系統疾病患病率的上升、有利的法規環境、醫療保健支出的成長、設備技術的顯著進步以及對微創（MI）療法日益成長的需求，而這些需求又得益於對研發（R&D）的大力投入。

神經調控市場的發展趨勢：

慢性疾病和神經系統疾病的盛行率不斷上升

糖尿病、肥胖症和心血管疾病等慢性病以及帕金森氏症、癲癇和憂鬱症神經系統疾病的日益普遍，是推動神經調控市場發展的重要因素。根據美國疾病管制與預防中心（CDC）統計，美國十分之六的成年人患有慢性病，十分之四的成年人患有兩種或兩種以上的慢性病。在印度，約21%的老年人患有至少一種慢性病。農村地區老年人中，17%患有至少一種慢性病；都市區老年人中，比例高達29%。雖然這些健康問題可能導致併發症，但可以透過神經調控療法進行管理或治療。例如，脊髓刺激（SCS）被廣泛用於緩解腰椎手術失敗症候群和複雜性局部疼痛症候群等相關症狀引起的疼痛。

醫療費用增加

在全球許多國家，神經調控技術的應用正在不斷推進，這主要得益於醫療成本的上升、中產階級的壯大以及先進醫療基礎設施的建設。例如，印度的公共醫療支出在2023年達到GDP的2.1%，2022年則為2.2%。印度政府也計劃推出價值5兆盧比（約68億美元）的稅收優惠政策，以加強該國的醫療基礎建設。同樣，在歐洲，2022年政府醫療支出總額達1.22兆歐元，佔GDP的7.7%。美國的醫療支出成長了4.1%，達到4.5兆美元，即人均13,493美元。這種成長正推動神經調控產業的地理擴張，並將這些先進治療方法引入更多患者群體。

引入優惠的還款政策

神經調控報銷政策的持續改善是市場成長的主要驅動力。在許多國家，健康保險公司已認知到神經調控在治療疑難雜症方面的有效性，並修訂了政策，將多種神經調控療法納入醫療保險範圍。這些變化使得更多患者能夠獲得神經調控技術。根據美國人口普查局統計，2022年，92.1%的美國人（約3.04億人）在當年擁有醫療保險。此外，私人醫療保險的覆蓋率達到65.6%，遠高於公共醫療保險的36.1%。保險公司也意識到神經調控的長期成本效益，尤其是在減少住院時間和藥物使用方面，這也促進了醫療覆蓋範圍的擴大。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球神經調控市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依技術分類

  • 內細胞神經調控
    • 主要部分
      • 脊髓刺激（SCS）
      • 深部腦部刺激（DBS）
      • 迷走神經刺激術（VNS）
      • 薦椎神經刺激（SNS）
      • 胃電刺激（GES）
  • 體外神經調控
    • 主要部分
      • 經皮電神經刺激（TENS）
      • 經顱磁刺激（TMS）
      • 其他

第7章 市場區隔：依生物材料分類

  • 金屬生物材料
  • 以聚合物為基礎的生物材料
  • 陶瓷生物材料

第8章 市場區隔：依應用領域分類

  • 帕金森氏症
  • 癲癇
  • 憂鬱症
  • 肌張力不全症
  • 疼痛管理
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbott Laboratories
    • Bioventus Inc.
    • Boston Scientific Corporation
    • Helius Medical Technologies
    • Integer Holdings Corporation
    • LivaNova PLC
    • Medtronic plc
    • MicroTransponder Inc.
    • Neuronetics
    • NeuroPace Inc.
    • NeuroSigma Inc.
    • Nevro Corp.
Product Code: SR112026A5722

The global neuromodulation market size reached USD 8.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 19.0 Billion by 2034, exhibiting a growth rate (CAGR) of 8.48% during 2026-2034. The market is experiencing robust growth, driven by the increasing prevalence of chronic and neurological disorders, imposition of favorable regulatory environment, rising expenditure on healthcare, significant advancements in device technology, and growing demand for minimally invasive (MI) therapies, supported by strong investment in research and development (R&D) initiatives.

Neuromodulation Market Analysis:

Major Market Drivers: The neuromodulation market is driven by the increasing prevalence of chronic diseases and neurological disorders, such as Parkinson's disease, chronic pain, and depression. Moreover, the rising expenditure on healthcare, the implementation of favorable regulations that offer improvements in reimbursement policies, and rapid technological advancements in neuromodulation devices, including the development of magnetic resonance imaging (MRI)-safe and rechargeable devices, are boosting the market growth.

Key Market Trends: There is a trend towards the integration of artificial intelligence (AI) and machine learning (ML) technologies into neuromodulation devices that enable real-time monitoring and adjustments of therapy. Moreover, the expansion of indications for neuromodulation therapies, facilitated by ongoing research and successful clinical trials, is broadening the market expansion.

Geographical Trends: North America dominates the neuromodulation market due to its advanced healthcare infrastructure, robust regulatory framework, and high healthcare expenditure. Other regions are also experiencing rapid growth, driven by improving healthcare infrastructures, increasing disposable incomes, and growing awareness of neuromodulation therapies.

Competitive Landscape: Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., and Nevro Corp., among many others.

Challenges and Opportunities: A major challenge is the high cost of devices and procedures, which can limit market penetration, especially in developing regions. Additionally, the complexity of device implantation and potential side effects pose hurdles. However, opportunities lie in the expanding scope of neuromodulation applications, including potential treatments for untapped medical conditions, such as obesity and addiction. Furthermore, increasing healthcare spending presents a significant opportunity for market expansion into previously underserved areas.

Neuromodulation Market Trends:

Rising Prevalence of Chronic Diseases and Neurological Disorders

The heightened incidence of chronic diseases such as diabetes, obesity, and cardiovascular conditions, alongside neurological disorders like Parkinson's disease, epilepsy, and depression, is a significant driver for the neuromodulation market. As per the Centre for Disease Control and Prevention (CDC), 6 in 10 adults in the U.S. are suffering from chronic diseases. And 4 out of 10 people have more than two chronic conditions. Also, about 21% of the geriatric adults in India have at least one chronic disease. 17% of geriatric people in rural areas and 29% in urban areas suffer from at least one chronic disease. These health issues lead to complications that can be managed or treated through neuromodulation therapies. For instance, spinal cord stimulation (SCS) is widely used for pain relief in conditions that result from failed back surgery syndrome or complex regional pain syndrome.

Increasing Expenditure on Healthcare

Several countries across the globe are witnessing increased adoption of neuromodulation therapies owing to rising expenditure on healthcare, the growing population of the middle class, and the establishment of advanced healthcare infrastructures. For instance, India's public expenditure on healthcare touched 2.1% of GDP in FY23 and 2.2% in FY22. Also, the Indian government is planning to introduce a credit incentive program worth Rs. 50,000 crores (US$ 6.8 billion) to boost the country's healthcare infrastructure. Similarly, in Europe, the general government spending on health amounted to €1.22 trillion or 7.7% of GDP in 2022. The U.S. healthcare spending saw a hike of 4.1%, reaching $4.5 trillion or $13493/person. This expansion is increasing the geographical footprint of the neuromodulation industry and introducing these advanced therapies to new patient populations.

Implementation of Favorable Reimbursement Policies

The ongoing improvements in reimbursement policies for neuromodulation procedures is a main factor driving the market growth. In many countries, health insurance providers have revised their policies to include several neuromodulation therapies as they recognize their benefits in treating many refractory conditions. These changes have made neuromodulation technologies more accessible to a broader range of patients. In 2022, 92.1 percent of people, or 304.0 million in the U.S., had health insurance at some point during the year, as per the U.S. Census Bureau. Moreover, private health insurance coverage was more prevalent than public coverage, at 65.6 percent and 36.1 percent, respectively. Also, insurers are recognizing the cost-effectiveness of neuromodulation in the long term, especially in terms of reduced hospital stays and medication use, which is expanding the scope of reimbursement coverage.

Neuromodulation Market Segmentation:

This report provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2026-2034. The report categorizes the market based on technology, biomaterial, and application.

Breakup by Technology:

  • Internal Neuromodulation
  • Spinal Cord Stimulation (SCS)
  • Deep Brain Stimulation (DBS)
  • Vagus Nerve Stimulation (VNS)
  • Sacral Nerve Stimulation (SNS)
  • Gastric Electrical Stimulation (GES)
  • External Neuromodulation
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Transcranial Magnetic Stimulation (TMS)
  • Others

Internal neuromodulation accounts for the majority of the market share

Based on the neuromodulation market analysis and forecast, internal neuromodulation emerged as the largest segment. It includes advanced therapies, such as spinal cord stimulation (SCS), deep brain stimulation (DBS), sacral nerve stimulation (SNS), and vagus nerve stimulation (VNS), among others. They are utilized for treating a wide range of chronic conditions and neurological disorders, including chronic pain, Parkinson's disease, urinary and fecal incontinence, and refractory epilepsy. Moreover, the proven efficacy of internal neuromodulations in improving patient outcomes, significant advancements in device technology that enhance user safety and comfort, and the broadening scope of clinical applications are fueling the neuromodulation market revenue.

Breakup by Biomaterial:

  • Metallic Biomaterials
  • Polymeric Biomaterials
  • Ceramic Biomaterials

Metallic biomaterials hold the largest share of the industry

As per the neuromodulation market report and overview, metallic biomaterials stand out as the largest segment, owing to their critical role in the manufacturing of implants and devices used in neuromodulation therapies, such as electrodes and leads. Metallic biomaterials are favored for their superior electrical conductivity, biocompatibility, and durability. They are essential for ensuring the long-term reliability and performance of neuromodulation devices, particularly those that require chronic implantation or are subject to bodily fluids and tissues. Besides this, the ongoing advancements that improve their functionality and safety, such as coatings to enhance biocompatibility or technologies to reduce the risk of infection, are favoring the neuromodulation market growth.

Breakup by Application:

  • Parkinson's Disease
  • Epilepsy
  • Depression
  • Dystonia
  • Pain Management
  • Others

Parkinson's disease represents the leading market segment

According to the neuromodulation market outlook and trends, Parkinson's disease emerged as the largest segment, reflecting the significant impact and utility of neuromodulation therapies in managing chronic neurological disorders. The increasing utilization of deep brain stimulation (DBS) for the treatment of patients who do not respond adequately to pharmacological treatments is enhancing the market growth. DBS helps in alleviating symptoms such as tremors, rigidity, and bradykinesia, significantly enhancing the quality of life for patients. Moreover, the efficacy of neuromodulation in providing substantial and sustained symptom relief, leading to its widespread adoption in clinical settings, is catalyzing the neuromodulation market share.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest neuromodulation market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for neuromodulation.

North America accounted for the largest segment in the neuromodulation market, attributed to several key factors, including advanced healthcare infrastructure, strong regulatory support, and substantial investments in research and development (R&D). Moreover, the region is a hub of some of the leading companies in the neuromodulation industry, which drives innovation and market growth through continuous advancements in technology. Additionally, the high prevalence of chronic diseases and neurological disorders, coupled with a well-established healthcare system that facilitates early adoption of new technologies, is contributing to the neuromodulation market revenue.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., Nevro Corp., etc.

The top neuromodulation companies are engaged in enhancing their competitive edge through strategic initiatives, such as mergers, acquisitions, and partnerships. They are investing in research and development (R&D) to innovate and improve their neuromodulation devices. These innovations focus on increasing the precision, effectiveness, and safety of therapies for conditions like chronic pain, Parkinson's disease, and urinary disorders. Additionally, industry leaders are involved in clinical trials to expand the indications for existing technologies, thereby broadening the potential user base. They are also prioritizing obtaining regulatory approvals in new markets to ensure global access to their advanced therapies. Furthermore, major companies are enhancing patient and practitioner engagement through digital platforms that facilitate better monitoring and management of therapy outcomes. This helps them align with the broader trend toward digital health solutions in medical technology, thereby positively impacting the neuromodulation market's recent development and opportunities.

Key Questions Answered in This Report

1. How big is the neuromodulation market?

2. What is the future outlook of neuromodulation market?

3. What are the key factors driving the neuromodulation market?

4. Which region accounts for the largest neuromodulation market share?

5. Which are the leading companies in the global neuromodulation market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neuromodulation Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Internal Neuromodulation
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Spinal Cord Stimulation (SCS)
      • 6.1.2.2 Deep Brain Stimulation (DBS)
      • 6.1.2.3 Vagus Nerve Stimulation (VNS)
      • 6.1.2.4 Sacral Nerve Stimulation (SNS)
      • 6.1.2.5 Gastric Electrical Stimulation (GES)
    • 6.1.3 Market Forecast
  • 6.2 External Neuromodulation
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
      • 6.2.2.2 Transcranial Magnetic Stimulation (TMS)
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Biomaterial

  • 7.1 Metallic Biomaterials
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymeric Biomaterials
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Ceramic Biomaterials
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Parkinson's Disease
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Epilepsy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Depression
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Dystonia
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Pain Management
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bioventus Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Boston Scientific Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Helius Medical Technologies
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Integer Holdings Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 LivaNova PLC
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Medtronic plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 MicroTransponder Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Neuronetics
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 NeuroPace Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 NeuroSigma Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Nevro Corp.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials

List of Figures

  • Figure 1: Global: Neuromodulation Market: Sales Value (in Billion USD), 2020-2025
  • Figure 2: Global: Neuromodulation Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 3: Global: Neuromodulation Market: Breakup by Technology (in %), 2025
  • Figure 4: Global: Neuromodulation Market: Breakup by Biomaterial (in %), 2025
  • Figure 5: Global: Neuromodulation Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Neuromodulation Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Neuromodulation (Internal Neuromodulation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Neuromodulation (Internal Neuromodulation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Neuromodulation (External Neuromodulation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Neuromodulation (External Neuromodulation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Neuromodulation (Metallic Biomaterials) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Neuromodulation (Metallic Biomaterials) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Neuromodulation (Polymeric Biomaterials) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Neuromodulation (Polymeric Biomaterials) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Neuromodulation (Ceramic Biomaterials) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Neuromodulation (Ceramic Biomaterials) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Neuromodulation (Parkinson's Disease) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Neuromodulation (Parkinson's Disease) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Neuromodulation (Epilepsy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Neuromodulation (Epilepsy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Neuromodulation (Depression) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Neuromodulation (Depression) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Neuromodulation (Dystonia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Neuromodulation (Dystonia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Neuromodulation (Pain Management) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Neuromodulation (Pain Management) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Neuromodulation (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Neuromodulation (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: North America: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: North America: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: United States: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: United States: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Canada: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Canada: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Asia-Pacific: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Asia-Pacific: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: China: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: China: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Japan: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Japan: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: India: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: India: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: South Korea: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: South Korea: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Australia: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Australia: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Indonesia: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Indonesia: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Others: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Others: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Europe: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Europe: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Germany: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Germany: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: France: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: France: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: United Kingdom: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: United Kingdom: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Italy: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Italy: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Spain: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Spain: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Russia: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Russia: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Others: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Others: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Latin America: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Latin America: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Brazil: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Brazil: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Mexico: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Mexico: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Middle East and Africa: Neuromodulation Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Middle East and Africa: Neuromodulation Market: Breakup by Country (in %), 2025
  • Figure 77: Middle East and Africa: Neuromodulation Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Global: Neuromodulation Industry: SWOT Analysis
  • Figure 79: Global: Neuromodulation Industry: Value Chain Analysis
  • Figure 80: Global: Neuromodulation Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neuromodulation Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Neuromodulation Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 3: Global: Neuromodulation Market Forecast: Breakup by Biomaterial (in Million USD), 2026-2034
  • Table 4: Global: Neuromodulation Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Neuromodulation Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Neuromodulation Market: Competitive Structure
  • Table 7: Global: Neuromodulation Market: Key Players